Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data.

Abstract excerpt

BACKGROUND: Approximately 17% of patients with non-small cell lung cancer (NSCLC) have epidermal growth factor receptor mutations (EGFRm). Amivantamab received United States Food and Drug Administration approvals in advanced NSCLC for patients with EGFR exon 20 insertions (exon20ins) who progressed after platinum-based chemotherapy (PBC) on 05/21/2021, for first-line (1 L) EGFR exon20ins on 03/01/2024, and for...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Antineoplastic Agents